|
JP2011140527A
|
|
Dosage formulation of ultrasound contrast agent
|
|
WO2008060934A2
|
|
Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
|
|
US2007178166A1
|
|
Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
|
|
WO2007070852A2
|
|
Processes for making particle-based pharmaceutical formulations for parenteral administration
|
|
WO2007070843A2
|
|
Processes for making particle-based pharmaceutical formulations for oral administration
|
|
ZA200609760B
|
|
Ultrasound contrast agent dosage formulation
|
|
US2005271591A1
|
|
Ultrasound contrast agent dosage formulation
|
|
EP1667659A1
|
|
Injectable, oral, or topical sustained release pharmaceutical formulations
|
|
EP1609483A1
|
|
Ultrasound contrast agent dosage formulation
|
|
NZ551986A
|
|
Ultrasound contrast agent dosage formulation
|
|
AU2004320514A1
|
|
Ultrasound contrast agent dosage formulation
|
|
KR20070039027A
|
|
Ultrasound contrast agent dosage formulation
|
|
CN102600485A
|
|
Ultrasonic contrast medium dosage formula
|
|
AU2003279070A2
|
|
Sustained release porous microparticles for inhalation
|
|
US2004121005A1
|
|
Porous COX-2 inhibitor matrices and methods of manufacture thereof
|
|
US6730322B1
|
|
Matrices formed of polymer and hydrophobic compounds for use in drug delivery
|
|
US2004118007A1
|
|
Methods and apparatus for making particles using spray dryer and in-line jet mill
|
|
US2004121003A1
|
|
Methods for making pharmaceutical formulations comprising deagglomerated microparticles
|
|
US2002142050A1
|
|
Porous drug matrices and methods of manufacture thereof
|
|
US2003037459A1
|
|
Spray drying apparatus and methods of use
|
